|
Indianapolis, Ind. May 3, 2004
Congestive Heart Failure and Prostate Cancer Tests to Reach Premier
Customers
Roche Diagnostics and Premier Sign New Three-year Agreements
for Portfolio of Products
Roche Diagnostics Corporation announced it has signed new three-year
contracts with Premier Purchasing Partners, LLP to continue providing
Roche Diagnostics' instruments, reagents, and consumables to Premier
members for multiple product categories. Covered under these contracts
are the MODULAR® ANALYTICS and Integrated MODULAR®
ANALYTICS systems; the COBAS Integra® Systems; MODULAR
PRE-ANALYTICS Systems and VS II Automation Systems; MODULAR,
COBAS Integra, and Elecsys® reagent kits; automated and visual
urinalysis products and point-of-care coagulation products. The
test menu covered by these contracts includes proBNP, troponin T,
free Prostate-Specific Antigen (free-PSA), D-Dimer, which are measured
in patients with heart disease, prostate cancer and deep vein thrombosis
respectively. Therapeutic drug monitoring (TDM) and drugs-of-abuse
assays (DAT) are also part of the contract.
These new contracts continue a long-term relationship between Premier
and Roche Diagnostics which now include the areas of clinical chemistry
and immunochemistry instruments and reagents, blood glucose monitoring,
urinalysis, molecular testing, and point-of-care coagulation.
"Roche Diagnostics offers Premier members the broadest portfolio
of platforms and product categories to meet Premier membership's
diverse needs, from satellite facilities to central core labs,"
said Dick Aderman, Senior Vice President and General Manager, Roche
Centralized and Molecular Diagnostics. "We are delighted to
continue our long-time collaboration with Premier to help its members
increase laboratory efficiency and enhance patient care through
timely, actionable clinical information."
Premier, Inc., is a strategic alliance in U.S. healthcare, entirely
owned by more than 200 of the nations leading hospital and healthcare
systems. These systems operate or are affiliated with nearly 1,500
hospital facilities and hundreds of other healthcare sites. Premier
provides an array of resources supporting health services delivery
including group purchasing for more than $17 billion annually in
supplies and equipment.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's
leading innovation-driven healthcare groups. Its core businesses
are pharmaceuticals and diagnostics. Roche is number one in the
global diagnostics market, the leading supplier of pharmaceuticals
for cancer, and a leader in virology and transplantation. As a supplier
of products and services for the prevention, diagnosis, and treatment
of disease, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche employs approximately
62,000 people in 150 countries. The Group has alliances and research
and development agreements with numerous partners, including majority
ownership interests in Genentech and Chugai. Roche's Diagnostics
Division, the world leader in in-vitro diagnostics with a uniquely
broad product portfolio, supplies a wide array of innovative testing
products and services to researchers, physicians, patients, hospitals,
and laboratories worldwide. For further information, please visit
our websites www.roche.com
and www.roche-diagnostics.com.
ELECSYS, MODULAR and Design, and COBAS INTEGRA are trademarks of
a Member of the Roche Group. Premier is a trademark of Premier,
Inc.
For more information please contact:
Lori LeRoy
Roche Diagnostics Corporation
317-521-9157
lori.leroy@roche.com
|
